

WHAT IS CLAIMED IS:

1. A method of treating systemic lupus erythematosus in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a humanized anti-CD11a antibody which binds specifically to human CD11a I-domain, said antibody containing a heavy chain variable region comprising the amino acid sequence of (a) CDR1 (SEQ ID NO:10), CDR2 (SEQ ID NO:11) and CDR3 (SEQ ID NO:12) or (b) SEQ ID NO:5, and a light chain variable region comprising the amino acid sequence of (a) CDR1 (SEQ ID NO: 13), CDR2 (SEQ ID NO:14) and CDR3 (SEQ ID NO:15) or (b) SEQ ID NO:2.
- 5 2. The method of claim 1, wherein the humanized anti-CD11a antibody has all human kappa I consensus light chain framework residues.
3. The method of claim 1, wherein the humanized anti-CD11a antibody has human V_H subgroup III consensus heavy chain framework residue 93H.
- 10 4. The method of claim 1, wherein the humanized anti-CD11a antibody has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:5 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:2.
5. The method of claim 1, wherein the humanized anti-CD11a antibody is a full length antibody.
- 15 6. The method of claim 5, wherein the humanized anti-CD11a antibody is a human IgG.
7. The method of claim 1, wherein the humanized anti-CD11a antibody is bound to a cytotoxic agent.
- 20 8. A method of treating multiple sclerosis in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a humanized anti-CD11a antibody which binds specifically to human CD11a I-domain, said antibody containing a heavy chain variable region comprising the amino acid sequence of (a) CDR1 (SEQ ID NO:10), CDR2 (SEQ ID NO:11) and CDR3 (SEQ ID NO:12) or (b) SEQ ID NO:5, and a light chain variable region comprising the amino acid sequence of (a) CDR1 (SEQ ID NO: 13), CDR2 (SEQ ID NO:14) and CDR3 (SEQ ID NO:15) or (b) SEQ ID NO:2.
- 25

9. The method of claim 8, wherein the humanized anti-CD11a antibody has all human kappa I consensus light chain framework residues.
10. The method of claim 8, wherein the humanized anti-CD11a antibody has human V_H subgroup III consensus heavy chain framework residue 93H.
11. The method of claim 8, wherein the humanized anti-CD11a antibody has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:5 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:2.
- 5 12. The method of claim 8, wherein the humanized anti-CD11a antibody is a full length antibody.
13. The method of claim 12, wherein the humanized anti-CD11a antibody is a human IgG.
- 10 14. The method of claim 8, wherein the humanized anti-CD11a antibody is bound to a cytotoxic agent.